Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 216 of the 217 references it cites were found in a registry or an index.

Immunotherapies for hepatocellular carcinoma

Abstract

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib in the first line and regorafenib, cabozantinib or ramucirumab in the second line. In the past 5 years, immune-checkpoint inhibitors have revolutionized the management of HCC. The combination of atezolizumab and bevacizumab has been shown to improve overall survival relative to sorafenib, resulting in FDA approval of this regimen. More recently, durvalumab plus tremelimumab yielded superior overall survival versus sorafenib and atezolizumab plus cabozantinib yielded superior progression-free survival. In addition, pembrolizumab monotherapy and the combination of nivolumab plus ipilimumab have received FDA Accelerated Approval in the second-line setting based on early efficacy data. Despite these major advances, the molecular underpinnings governing immune responses and evasion remain unclear. The immune microenvironment has crucial roles in the development and progression of HCC and distinct aetiology-dependent immune features have been defined. Inflamed and non-inflamed classes of HCC and genomic signatures have been associated with response to immune-checkpoint inhibitors, yet no validated biomarker is available to guide clinical decision-making. This Review provides information on the immune microenvironments underlying t…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-021-00573-2

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 217 references

Research works printed but not linked: 2

  1. Tabrizian, P. et al. A US multicenter analysis of 2529 HCC patients undergoing liver transplantation: 10‐year outcome assessing the role of down‐staging to within Milan criteria. Hepatology 70, 10A–11A (2019).
  2. AstraZeneca. Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer. astrazeneca.com, https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer.html (15 October 2021).

Cited by

See all 1,843

Metadata

Authors
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S.
Affiliations
  • Institució Catalana de Recerca i Estudis Avançats (ES)
  • Hospital Clínic de Barcelona (ES)
  • University College London (GB)
  • University of Milan (IT)
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • Hebrew University of Jerusalem (IL)
  • Massachusetts General Hospital (US)
  • University of California, Los Angeles (US)
Corresponding author
Llovet, Josep M.
Venue
Nature Reviews Clinical Oncology
Published
2021-11-11
Volume
19
Issue
3
Pages
151-172
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3212903603
Cited by
1,843
References
217
Citations by year
2026: 306 · 2025: 406 · 2024: 498 · 2023: 428 · 2022: 204
FWCI
37.67
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust (214191/Z/18/Z, PS3416)
  • Cancer Research UK (26603, 26813, C57701/A26137)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056621, R01DK128289)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
hepatocellular carcinoma, immune checkpoint inhibitors, tumor immune microenvironment, atezolizumab, bevacizumab, durvalumab, tremelimumab, pembrolizumab, nivolumab, ipilimumab, immune evasion, immune-related adverse events, immunotherapy resistance, first-line and second-line therapy, liver cancer
MeSH terms
Sorafenib, Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapies for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41571-021-00573-2
The paper
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022). Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00573-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.